Neurocrine
As of the edition of 20 October 2026, Neurocrine runs 19 drugs, 4 of them marketed; it is on route A at 5 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
- Capnia, Inc.: renamed in 2017
- Soleno Therapeutics, Inc.: acquired in 2026; successor NEUROCRINE BIOSCIENCES INC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 6 |
| Went quiet | 2 |
| Stopped | 5 |
| Status not established | 2 |
| Total | 19 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Opicapone | Ends 2032 (patent) | 2 |
| Valbenazine | Ends 2036 (patent) | 2 |
| Diazoxide | none listed | 0 |
| Crinecerfont | Ends 2043 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 2 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where Neurocrine needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 43 trials led
- Mental health: 38 trials led
- Inherited and neonatal: 19 trials led